Open AccessA novel combination treatment against melanoma with NRAS mutation and therapy resistance
Author(s) -
Yu Yanlin
Publication year - 2018
Publication title -
embo molecular medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.923
H-Index - 107
eISSN - 1757-4684
pISSN - 1757-4676
DOI - 10.15252/emmm.201708573
Subject(s) - neuroblastoma ras viral oncogene homolog , mutation , melanoma , microbiology and biotechnology , cancer research , medicine , biology , genetics , gene , kras
Targeted cancer therapies have shown some progress in treating BRAF ‐mutant melanoma, but not against NRAS ‐mutant and treatment‐resistant melanoma. In this issue of EMBO Molecular Medicine , Echevarría‐Vargas et al ([Echevarría‐Vargas IM, 2018]) report that cotargeting BET and MEK pathways efficiently kills immune therapy‐resistant and NRAS ‐mutant melanoma tumor cells.